NCT02609737已完成不适用
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and the willingness to sign a written informed consent document
- •Adults ≥ 18 years old
- •Histologically or cytologically confirmed metastatic and/or unresectable progressive, well differentiated carcinoid or pancreatic NET carcinoids
- •Progressive metastatic disease defined by one of the following, occurring within 6 months of study entry:
- •At least a 20% increase in radiologically or clinically measurable disease
- •Appearance of any new lesion
- •Symptomatic disease (including worsening hormonal symptoms or symptoms related to tumor burden)
- •Measurable disease as defined by RECIST 1.
- •At least one metastasis must show uptake of 111In-DTPA-octreotide on SPECT that is higher than the physiologic radiotracer uptake by the liver
- •ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
- •Patients must have normal organ and marrow function as defined below:
- •Leukocytes ≥ 3.0 x 109/L
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
- •Hemoglobin ≥ 9.0 g/dL
- •Platelets ≥ 200 x 10^9/L
- •Total bilirubin ≤ 1.25 x Upper Limit Normal (ULN)
- •AST (SGOT)/ ALT(SGPT) ≤ 2.5 x ULN with liver metastases
- •Alkaline phosphatase < 2 x ULN (if known liver or bone disease)
- •Serum albumin > 30 g/L, or serum albumin = 30 g/L but normal prothrombin time
- •Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) calculated CrCl ≥ 60 mL/min/1.73m^2
- •Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
- •Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed > 6 weeks prior to study entry. For such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entry.
- •Previous chemotherapy and/or investigational agents are allowed if completed > 4 weeks prior to study entry (> 6 weeks if last regimen contained bis-chloroethyl nitrosourea (BCNU) or mitomycin C). For patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry.
- •Patients must not have disease that is currently amenable to surgery. Prior surgery is allowed no less than 6 weeks prior to study entry.
排除标准
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-JR11 as assessed from medical records
- •Life expectancy < 6 months as assessed by the treating physician.
- •Treatment with short-acting somatostatin analogs less than 3 days and Sandostatin® depot injection less than 5 weeks before scanning and treatment
- •Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Women who are pregnant or breastfeeding
- •Toxicities from prior therapies that have not resolved to grade 1 or grade 0
- •Known CNS metastases and/or carcinomatous meningitis
- •Active malignancy of metastatic potential other than the known carcinoid or pancreatic NET within the past three years
- •>20% bone marrow external beam radiotherapy and/or previous radioisotope therapy
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: 2 years
according to RECIST 1.1 and median progression-free and overall survival will be estimated and reported with 95% confidence intervals
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study of ASN003 in Subjects With Advanced Solid TumorsNeoplasmsColorectal NeoplasmCarcinoma, Non-small Cell LungMelanomaNCT02961283Asana BioSciences24
进行中（未招募）
3 期
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate CancerProstate CancerNCT04557501Centre hospitalier de l'Université de Montréal (CHUM)800
已完成
3 期
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)Eosinophilic EsophagitisNCT03633617Regeneron Pharmaceuticals321
招募中
3 期
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal CancerColon or Upper Rectum AdenocarcinomaNCT06197425Centre Hospitalier Universitaire Dijon1,660
已完成
3 期
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and ElderlyInfluenzaNCT00306527Novartis Vaccines2,235